GlassScriptPhysician profile
Todd C Bryant
NPI 1932724366
$2,243.69
in general payments reported to CMS, 2019-2025
14 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $129 · 2022: $656 · 2023: $471 · 2024: $740 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,447 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,446.66 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $496.50 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $452.53 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $348.79 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $164.99 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Abbvie INC. | $163.70 | 2024-2025 | |
| Lilly USA, LLC | $146.36 | 2022-2024 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $139.43 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Grifols USA, LLC | $124.99 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.47 | 2021-2022 | |
| Astellas Pharma US INC | $41.01 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.70 | 2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $37.57 | 2022 | |
| Pfizer INC. | $23.80 | 2024 | |
| Dexcom, INC. | $20.85 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Bryant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.